Published in Nanomedicine on May 13, 2013
Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS (2013) 1.73
Getting into the brain: Potential of nanotechnology in the management of NeuroAIDS. Adv Drug Deliv Rev (2016) 0.98
Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapies. Curr Med Chem (2014) 0.94
Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. Retrovirology (2015) 0.92
Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials (2014) 0.90
Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J Virol (2014) 0.88
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Prolonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages. Sci Rep (2015) 0.85
Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice. Antiviral Res (2015) 0.81
The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy. Nanomedicine (2015) 0.81
Pharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations. Antimicrob Agents Chemother (2014) 0.80
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery. J Control Release (2015) 0.78
Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine (Lond) (2016) 0.78
Investigational reverse transcriptase inhibitors for the treatment of HIV. Expert Opin Investig Drugs (2015) 0.78
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J Clin Invest (2017) 0.77
Magnetic resonance imaging of folic acid-coated magnetite nanoparticles reflects tissue biodistribution of long-acting antiretroviral therapy. Int J Nanomedicine (2015) 0.77
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy. PLoS One (2015) 0.76
Creation of a Long-Acting Nanoformulated 2',3'-Dideoxy-3'-Thiacytidine. J Acquir Immune Defic Syndr (2016) 0.76
Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages. PLoS One (2017) 0.75
Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine (2016) 0.75
Generation and Disease Model Relevance of a Manganese Enhanced Magnetic Resonance Imaging-Based NOD/scid-IL-2Rγ c (null) Mouse Brain Atlas. J Neuroimmune Pharmacol (2015) 0.75
Investigational protease inhibitors as antiretroviral therapies. Expert Opin Investig Drugs (2016) 0.75
Nanomedicines for dysfunctional macrophage-associated diseases. J Control Release (2017) 0.75
Long-acting slow effective release antiretroviral therapy. Expert Opin Drug Deliv (2017) 0.75
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med (2002) 4.73
Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol (1990) 4.37
Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science (1994) 4.36
Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns (2002) 4.30
Antiretroviral therapy and management of HIV infection. Lancet (2010) 2.84
Adherence to HAART regimens. AIDS Patient Care STDS (2003) 2.27
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J Immunol (1991) 1.92
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Folate receptor beta is expressed by tumor-associated macrophages and constitutes a marker for M2 anti-inflammatory/regulatory macrophages. Cancer Res (2009) 1.71
Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis (2009) 1.64
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Current status and challenges of antiretroviral research and therapy. Antiviral Res (2009) 1.52
A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood (2008) 1.49
Endocytosis of folate-protein conjugates: ultrastructural localization in KB cells. J Cell Sci (1993) 1.44
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano (2009) 1.29
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials (2011) 1.21
Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int J Nanomedicine (2011) 1.11
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine (2012) 1.08
In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine (2011) 1.05
Targeting anti-HIV drugs to the CNS. Expert Opin Drug Deliv (2009) 1.05
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 1.05
Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. J Vis Exp (2010) 1.03
Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J Membr Biol (1997) 1.03
Cell delivery of therapeutic nanoparticles. Prog Mol Biol Transl Sci (2011) 0.97
A folate receptor beta-specific human monoclonal antibody recognizes activated macrophage of rheumatoid patients and mediates antibody-dependent cell-mediated cytotoxicity. Arthritis Res Ther (2011) 0.95
Targeting of nanoparticles: folate receptor. Methods Mol Biol (2010) 0.90
Folate-linked lipid-based nanoparticles deliver a NFkappaB decoy into activated murine macrophage-like RAW264.7 cells. Biol Pharm Bull (2006) 0.84
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Endocytosis of nanomedicines. J Control Release (2010) 3.23
Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release (2008) 2.63
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Human immunodeficiency virus type 1 pathobiology studied in humanized BALB/c-Rag2-/-gammac-/- mice. J Virol (2006) 2.24
Nanosized cationic hydrogels for drug delivery: preparation, properties and interactions with cells. Adv Drug Deliv Rev (2002) 2.19
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood (2006) 2.13
Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Am J Pathol (2007) 2.05
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 2.01
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Nanogels for oligonucleotide delivery to the brain. Bioconjug Chem (2004) 1.94
Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol (2009) 1.85
Oxidative stress and the pathogenesis of neurodegenerative disorders. Int Rev Neurobiol (2007) 1.84
Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukoc Biol (2007) 1.80
CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease. J Neuroimmune Pharmacol (2012) 1.78
HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab (2006) 1.72
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) (2009) 1.72
Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res (2008) 1.67
Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One (2008) 1.65
Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol (2003) 1.62
Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther (2003) 1.61
A functional transsulfuration pathway in the brain links to glutathione homeostasis. J Biol Chem (2006) 1.61
STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood (2007) 1.60
Public health triangulation: approach and application to synthesizing data to understand national and local HIV epidemics. BMC Public Health (2010) 1.57
Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J Immunol (2010) 1.57
NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) (2009) 1.55
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine (Lond) (2011) 1.52
Polyplex Nanogel formulations for drug delivery of cytotoxic nucleoside analogs. J Control Release (2005) 1.52
Quantitative diffusion tensor imaging detects dopaminergic neuronal degeneration in a murine model of Parkinson's disease. Neurobiol Dis (2007) 1.52
Neuroinflammation, Oxidative Stress and the Pathogenesis of Parkinson's Disease. Clin Neurosci Res (2006) 1.50
A coat of many colors: neuroimmune crosstalk in human immunodeficiency virus infection. Neuron (2009) 1.48
Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. Am J Pathol (2005) 1.46
HIV-1-associated dementia: a metabolic encephalopathy perpetrated by virus-infected and immune-competent mononuclear phagocytes. J Acquir Immune Defic Syndr (2002) 1.46
Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood (2010) 1.44
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol (2010) 1.42
Biochemical and biologic characterization of exosomes and microvesicles as facilitators of HIV-1 infection in macrophages. J Immunol (2012) 1.42
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology (2006) 1.41
Polymer micelle with cross-linked ionic core. J Am Chem Soc (2005) 1.40
HIV-1-infected and/or immune activated macrophages regulate astrocyte SDF-1 production through IL-1beta. Glia (2006) 1.40
Observing supernova 1987A with the refurbished Hubble Space Telescope. Science (2010) 1.39
A macrophage-nanozyme delivery system for Parkinson's disease. Bioconjug Chem (2007) 1.38
Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol (2006) 1.37
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
Cell-mediated drug delivery. Expert Opin Drug Deliv (2011) 1.33
Different internalization pathways of polymeric micelles and unimers and their effects on vesicular transport. Bioconjug Chem (2008) 1.33
Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS (2012) 1.32
HIV-1 neuroimmunity in the era of antiretroviral therapy. Neurobiol Dis (2010) 1.32
Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One (2009) 1.31
Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug Chem (2008) 1.31
Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology (2007) 1.30
Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci (2003) 1.28
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release (2010) 1.28
Polymer micelles with cross-linked ionic cores for delivery of anticancer drugs. J Control Release (2006) 1.28
Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J Immunol (2009) 1.27
Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci (2009) 1.27
Osterix/Sp7 regulates mesenchymal stem cell mediated endochondral ossification. J Cell Physiol (2008) 1.27
CD8+ cell depletion accelerates HIV-1 immunopathology in humanized mice. J Immunol (2010) 1.27
Polypeptide point modifications with fatty acid and amphiphilic block copolymers for enhanced brain delivery. Bioconjug Chem (2005) 1.26
Design and formulation of polyplexes based on pluronic-polyethyleneimine conjugates for gene transfer. Bioconjug Chem (2002) 1.25
CNS expression of anti-inflammatory cytokine interleukin-4 attenuates Alzheimer's disease-like pathogenesis in APP+PS1 bigenic mice. FASEB J (2010) 1.25
Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis (2012) 1.23
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Loss of neuronal integrity during progressive HIV-1 infection of humanized mice. J Neurosci (2011) 1.22
Regulation of tissue inhibitor of metalloproteinase-1 by astrocytes: links to HIV-1 dementia. Glia (2003) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
Novel dexamethasone-HPMA copolymer conjugate and its potential application in treatment of rheumatoid arthritis. Arthritis Res Ther (2007) 1.21
Folate-decorated nanogels for targeted therapy of ovarian cancer. Biomaterials (2011) 1.21
Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal (2009) 1.20
The effect of the nonionic block copolymer pluronic P85 on gene expression in mouse muscle and antigen-presenting cells. Biomaterials (2008) 1.19
Heparin-loaded zein microsphere film and hemocompatibility. J Control Release (2005) 1.17
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob Agents Chemother (2013) 1.17
The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials (2009) 1.17
Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem (2007) 1.17
Sensitization of cells overexpressing multidrug-resistant proteins by pluronic P85. Pharm Res (2003) 1.17
Doubly amphiphilic poly(2-oxazoline)s as high-capacity delivery systems for hydrophobic drugs. Biomaterials (2010) 1.16
CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol (2007) 1.16
Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release (2005) 1.16
Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci (2005) 1.16
Ion channel blockade attenuates aggregated alpha synuclein induction of microglial reactive oxygen species: relevance for the pathogenesis of Parkinson's disease. J Neurochem (2007) 1.15
Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol (2008) 1.15
Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14